Physician profile
Ted B Walker
NPI 1467833301
$9,052.98
in general payments reported to CMS, 2019-2025
36 companies · $2,733 in 2025
The $2,733 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2021: $40.40 · 2022: $966 · 2023: $2,560 · 2024: $2,647 · 2025: $2,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,908 · Education: $32.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,907.65 |
| Education | $32.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,747.70 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,116.71 | 2022-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $750.38 | 2022-2025 | Xifaxan |
| Pfizer INC. | $695.15 | 2021-2025 | |
| Genzyme Corporation | $661.15 | 2022-2025 | |
| Celgene Corporation | $450.10 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $434.15 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $413.63 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $381.89 | 2022-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $328.66 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $272.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $244.56 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $203.77 | 2022-2025 | |
| Amgen INC. | $159.25 | 2022-2025 | Avsola, Amjevita, Uplizna |
| Lilly USA, LLC | $133.77 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $133.05 | 2022-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $109.08 | 2022-2025 | |
| Dova Pharmaceuticals | $86.67 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $83.75 | 2024-2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.81 | 2023-2024 | Cyltezo |
| Mallinckrodt Hospital Products INC. | $71.45 | 2023-2024 | Terlivaz |
| Organon LLC | $67.85 | 2023-2024 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $61.08 | 2023 | |
| Ironwood Pharmaceuticals, INC | $57.75 | 2022-2024 | |
| Celltrion USA INC. | $51.52 | 2023-2024 | Yuflyma, Zymfentra |
| Mylan Institutional INC. | $42.51 | 2023 | |
| Novo Nordisk INC | $32.11 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $31.60 | 2023 | Idacio |
| Braintree Laboratories, INC. | $23.97 | 2025 | Suflave |
| Sandoz INC. | $23.46 | 2024 | Hyrimoz |
| Dynavax Technologies Corporation | $22.66 | 2025 | Heplisav-B |
| Shionogi INC | $19.96 | 2019 | |
| Capsovision, INC. | $19.23 | 2024 | Capsocam Plus |
| Medtronic, INC. | $17.55 | 2024 | Interstim |
| Phathom Pharmaceuticals, INC. | $15.59 | 2024 | Voquezna |
| Redhill Biopharma INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.